Gulf War Illness, Clinical Evaluation Award | W81XWH 19 GWIRP CEA

Opportunity Information: Apply for W81XWH 19 GWIRP CEA

The Gulf War Illness (GWI) Clinical Evaluation Award (FY19) is a Department of Defense research funding opportunity aimed at moving the most credible Gulf War Illness science closer to real-world clinical use in Gulf War Veterans. The central purpose is translation: taking validated GWI research results, including replicated and well-qualified preclinical findings, and testing or verifying them in a Gulf War Veteran population. This mechanism is positioned in the "Verification" phase of the program's research pipeline, meaning applicants are expected to build on a solid foundation of prior evidence rather than start from early discovery or exploratory work. In practical terms, the program is looking for studies that can confirm whether a promising biomarker, mechanism, or early intervention signal actually holds up in appropriately designed human research involving Gulf War Veterans.

The award specifically encourages two main types of projects. The first is statistically powered biomarker trials that can validate biomarkers for Gulf War Illness, with the expectation that these biomarkers could eventually function as clinical endpoints in later, larger clinical trials (typically Phase IIb to Phase III). The second is proof-of-concept intervention trials, such as pilot studies, first-in-human work, or early phase clinical trials (roughly Phase I through Phase IIa). These intervention studies can include drug or biologic candidates, devices, clinical guidance approaches, or other technologies, as long as they are supported by strong objective evidence in the GWI field. The program will consider repurposed treatments originally developed for other conditions that share symptoms with GWI, but it signals a preference for projects that directly translate qualified results generated within the Gulf War Illness research community, rather than relying mainly on analogies to other disorders.

A key feature of this announcement is its explicit clinical trial definition. Under this opportunity, a clinical trial is any research study where one or more human subjects are prospectively assigned to one or more interventions (including placebo or other controls) to evaluate effects on biomedical or behavioral health-related outcomes. This definition matters because it clarifies what the sponsor considers a clinical trial and, by extension, the level of rigor and planning expected. The interventions contemplated are broad: they may be pharmacologic agents (drugs or biologics), devices, clinical or behavioral guidance, or enabling technologies, and the announcement also allows studies that test repurposing of FDA-approved drugs.

For biomarker-focused applications, the expectations are fairly strict. Biomarker investigations must go beyond preliminary observations and include a Gulf War Illness cohort large enough to produce statistically meaningful results. The intended payoff is not simply reporting an association, but generating evidence strong enough to support the biomarker's future use as a validated clinical endpoint in larger confirmatory trials. This emphasis on statistical power and endpoint validation reflects the award's placement in the verification stage, where reproducibility and clinical interpretability become more important than novelty.

Eligibility is described as unrestricted, meaning a wide range of organizations can apply, subject to any additional eligibility language in the full announcement. The sponsor is the Department of Defense, Department of the Army, through USAMRAA, and the funding instruments listed include both grants and cooperative agreements, indicating that some awards may involve a more hands-on federal role in project coordination compared with a standard grant. The CFDA number associated with the opportunity is 12.420, and the activity category is science and technology research and development.

Programmatic requirements emphasize feasibility and access. Because the funded work must be conducted in a Gulf War Veteran population, applicants are expected to demonstrate that they can actually recruit or access the required cohort(s). The announcement also calls for proof of availability and access to any critical reagents needed to carry out the study, which is another way of screening for projects that are realistically ready to execute. Applications must present a believable clinical investigation timeline, and budgets must match the proposed trial phase and scale. Notably, the listed award ceiling is shown as 0 in the summary data, which typically means the ceiling is not captured in that excerpt or is specified elsewhere in the full funding announcement; applicants are directed to the funding restrictions section for the controlling details. The opportunity anticipated making about two awards, underscoring that this is a relatively selective competition designed to fund a small number of well-justified, clinically ready projects.

In terms of timing and administrative details, the opportunity number is W81XWH-19-GWIRP-CEA. It was created on May 16, 2019, with an original closing date of October 3, 2019. Overall, the Clinical Evaluation Award is best understood as a bridge between strong preclinical or early human findings and larger, definitive clinical trials, with a clear requirement that the work be conducted in Gulf War Veterans and structured to produce results that can stand up as meaningful clinical evidence.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "Gulf War Illness, Clinical Evaluation Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 16, 2019.
• Applicants must submit their applications by Oct 03, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 GWIRP CEA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: